March 3, 2020

James Dalton, PhD, Dean of the University of Michigan College of Pharmacy, was recently elected as an American Association for the Advancement of Science Member-at-Large on Pharmaceutical Sciences. As a Member-at-Large, Dean Dalton will participate in nominating and voting on elected Fellows for the Association, appointing a Section Secratary, and more. 

Dean Dalton is widely recognized for his research on selective androgen receptor modulators (SARMs). In 1997, Dean Dalton’s group was the first to report on SARMs, a discovery that launched a new class of potential drugs to treat age and disease-related muscle loss. In October 2019, Dean Dalton was inducted into the National Academy of Medicine, one of health and medicine's highest honors. 

Dean Dalton earned a Bachelor of Science in pharmacy from the University of Cincinnati and a PhD in pharmaceutics and pharmaceutical chemistry from Ohio State. He was a staff pharmacist at Kettering Medical Center in Kettering, Ohio, and had a postdoctoral fellowship in the Division of Pharmaceutics and Pharmaceutical Chemistry at Ohio State. He went on to become an assistant/associate professor at the University of Tennessee (1992-2000) and professor and chair in the Division of Pharmaceutics at Ohio State (2000-2007). He left on an entrepreneurial leave of absence from Ohio State in 2005 to join the small, Memphis-based drug development company GTx Inc. as vice president of preclinical research and development and chief scientific officer to advance the clinical development of SARMs. He stayed at GTx through 2014, then joined U-M as professor and dean of the College of Pharmacy. He also serves as a Chair for Michigan Drug Discovery's Executive Committee.